Merus' IPO

Merus raised a round of funding on May 19, 2016. Investors include Public.

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured …

Articles about Merus' IPO: